Breaking News Instant updates and real-time market news.

BIIB

Biogen

$318.11

-0.21 (-0.07%)

, LLY

Eli Lilly

09:31
11/23/16
11/23
09:31
11/23/16
09:31

Biogen selloff may be an overreaction, says Jefferies

Jefferies analyst Brian Abrahams believes selloff in shares of Biogen (BIIB) following Eli Lilly's (LLY) Alzheimer's failure may be an overreaction. Signals of activity seen for Lilly's sola "do maintain some possibility" that Biogen's aducanumab could "ultimately make it over the line," Abrahams tells investors in a research note. He keeps a Hold rating on Biogen with a $310 price target, however, viewing the risk/reward as balanced.

BIIB

Biogen

$318.11

-0.21 (-0.07%)

LLY

Eli Lilly

  • 29

    Nov

  • 04

    Dec

BIIB Biogen
$318.11

-0.21 (-0.07%)

11/23/16
SBSH
11/23/16
NO CHANGE
Target $305
SBSH
Neutral
Citi pegs potential Biogen downside to $287 on Lilly failure
In a research note dated yesterday, Citi analyst Robyn Karnauskas said shares of Biogen (BIIB) could fall to $286 should Eli Lilly's (LLY) Alzheimer's drug solanezumab fail in its Phase 3 study. After Lilly reported this morning that the trial failed, shares of Biogen are down 6%, or $18.60, to $299.51 in pre-market trading. Shares of Lilly are down 14%, or $10.77, to $65.22. Karnauskas estimated the downside range of Biogen on a failed solanezumab study at $287-$306. The analyst has a Neutral rating on Biogen.
11/23/16
PIPR
11/23/16
NO CHANGE
PIPR
Overweight
Piper's Schimmer proclaims amyloid hypothesis is not dead
Piper Jaffray analyst Joshua Schimmer says the failure of Eli Lilly's (LLY) solanezumab is not the final nail in the amyloid hypothesis coffin. Biogen (BIIB) and Eisai's aducanimab study is the most potent approach for amyloid lowering, Schimmer tells investors in a research note. He points out that he was skeptical whether solanezumab's effect was adequate. "Our view of Alzheimer's for amyloid is informed not so much by the extremely sloppy science in that disease, but by consistent cause/effect signals across other amyloidosis," Schimmer writes. He believes today's selloff in shares of Biogen "creates some breathing room." The analyst recommends looking to build a position in Biogen after the stock settles down. Schimmer reiterates an Overweight rating on the shares with a $335 price target. The stock is down 8%, or $24.41, to $293.70 in pre-market trading.
11/23/16
MSCO
11/23/16
NO CHANGE
MSCO
Overweight
Morgan Stanley expects big reversal today in Biogen shares
Morgan Stanley Matthew Harrison expects shares of Biogen (BIIB) to end the trading day flat or slightly higher. The stock is currently down $26.61, or 8%, to $291.50 in pre-market trading. With Biogen's aducanumab more potent than Eli Lilly's solanezumab, the Alzheimer's drug still has potential for success, Harrison tells investors in a research note. He points out that Lilly management noted that "the study results, including many secondary clinical endpoints, directionally favored solanezumab." Harrison sees hope in the amyloid hypothesis. The analyst has an Overweight rating on Biogen.
11/23/16
SBSH
11/23/16
NO CHANGE
Target $305
SBSH
Buy
Citi sees four reasons why Biogen Alzheimer's drug can still work
Citi analyst Robyn Karnauska sees four reasons why Biogen's (BIIB) Alzheimer's drug aducanumab can still work following the failure of Eli Lilly's (LLY) solanezumab. The analyst lists difference in mechanism of action, efficacy in an end-point-dependent manner, patient population and endpoints as why she thinks Biogen's drug can have a different outcome than Lilly's. The analyst has a Neutral rating on Biogen with a $305 price target.
LLY Eli Lilly

11/23/16
JPMS
11/23/16
NO CHANGE
Target $85
JPMS
Overweight
JPMorgan sees 'attractive opportunity' amid Eli Lilly selloff
JPMorgan analyst Chris Schott lowered his price target for Eli Lilly to $85 from $95 after the phase III trial of solanezumab missed on both primary and secondary endpoints. Beyond solanezumab, Lilly has a diverse range of new product opportunities that support 5% sales and mid-teens earnings growth, Schott tells investors in a research note. With the shares down 13% to $65.81 in pre-market trading, the analyst sees an "attractive opportunity." He keeps an Overweight rating on Lilly.
11/23/16
JEFF
11/23/16
NO CHANGE
Target $100
JEFF
Buy
Eli Lilly still expects to grow revenue, says Jefferies
Jefferies analyst Jeffrey Holford says that while the solanezumab Phase III trial failure is disappointing, Eli Lilly management expects to grow revenue between 2015 and 2020 while expanding margins. Further, the company is still pursuing the Alzheimer's indication though a number of other programs, Holford tells investors in a research note. The analyst previously estimated a negative solanezumab trial outcome could see the stock down $12. Shares of Lilly are currently down $10.19 to $65.80 in pre-market trading. Holford keeps a Buy rating on Lilly with a $100 price target.

TODAY'S FREE FLY STORIES

SBCF

Seacoast Banking

$23.70

-0.53 (-2.19%)

14:33
02/21/17
02/21
14:33
02/21/17
14:33
Conference/Events
Seacoast Banking to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FXI

iShares Trust FTSE/Xinhua China 25 Fund

$38.76

0.3 (0.78%)

14:31
02/21/17
02/21
14:31
02/21/17
14:31
Options
Notable spreads in the Largecap China ETF »

Notable spreads in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEM

Newmont Mining

$37.35

0.34 (0.92%)

, WCN

Waste Connections

$83.81

0.2099 (0.25%)

14:29
02/21/17
02/21
14:29
02/21/17
14:29
Earnings
Notable companies reporting after market close »

Notable companies…

NEM

Newmont Mining

$37.35

0.34 (0.92%)

WCN

Waste Connections

$83.81

0.2099 (0.25%)

VRSK

Verisk Analytics

$84.90

0.63 (0.75%)

NFX

Newfield Exploration

$42.51

0.69 (1.65%)

KAR

KAR Auction

$46.55

0.07 (0.15%)

XPO

XPO Logistics

$48.60

-0.62 (-1.26%)

FSLR

First Solar

$34.84

0.73 (2.14%)

TXRH

Texas Roadhouse

$48.24

0.13 (0.27%)

TEX

Terex

$32.14

0.14 (0.44%)

PZZA

Papa John's

$86.01

-0.39 (-0.45%)

WLL

Whiting Petroleum

$11.61

0.5 (4.50%)

SPN

Superior Energy

$16.64

0.215 (1.31%)

DEPO

Depomed

$16.47

-0.38 (-2.26%)

RRGB

Red Robin

$47.80

0.05 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 24

    Feb

  • 26

    Feb

  • 01

    Mar

  • 05

    Mar

  • 07

    Mar

  • 07

    Mar

  • 13

    Mar

  • 14

    Mar

  • 14

    Mar

  • 15

    Mar

CDE

Coeur Mining

$9.20

0.315 (3.55%)

14:26
02/21/17
02/21
14:26
02/21/17
14:26
Options
Coeur Mining call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:25
02/21/17
02/21
14:25
02/21/17
14:25
General news
Canada Retail Sales Preview »

Canada Retail Sales…

14:25
02/21/17
02/21
14:25
02/21/17
14:25
Conference/Events
Leerink specialty pharma/biotech analysts hold analyst/industry conference call »

Specialty Pharmaceuticals…

VLKAY

Volkswagen

$30.87

-0.65 (-2.06%)

, TTM

Tata Motors

$34.20

0.74 (2.21%)

14:24
02/21/17
02/21
14:24
02/21/17
14:24
Periodicals
Volkswagen, Tata Motors in advanced partnership talks, Economic Times says »

Volkswagen (VLKAY) and…

VLKAY

Volkswagen

$30.87

-0.65 (-2.06%)

TTM

Tata Motors

$34.20

0.74 (2.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QSR

Restaurant Brands

$57.56

3.66 (6.79%)

, PLKI

Popeyes

$66.12

-0.26 (-0.39%)

14:24
02/21/17
02/21
14:24
02/21/17
14:24
Periodicals
Popeyes declined rival bid from Arby's, Bloomberg reports »

Popeyes Louisiana Kitchen…

QSR

Restaurant Brands

$57.56

3.66 (6.79%)

PLKI

Popeyes

$66.12

-0.26 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 23

    Feb

  • 23

    Mar

14:21
02/21/17
02/21
14:21
02/21/17
14:21
General news
Stocks drifting near all-time best levels »

Stocks remain in positive…

$NSD

NASDAQ Market Internals

14:18
02/21/17
02/21
14:18
02/21/17
14:18
Technical Analysis
NASDAQ Market Internals summary »

Breadth is bullish across…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:17
02/21/17
02/21
14:17
02/21/17
14:17
Technical Analysis
NYSE Market Internals summary »

Breadth is bullish across…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBI

Pitney Bowes

$13.74

0.35 (2.61%)

14:11
02/21/17
02/21
14:11
02/21/17
14:11
Options
Bullish option flow in Pitney Bowes »

Bullish option flow in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

HD

Home Depot

$144.01

1.0148 (0.71%)

14:08
02/21/17
02/21
14:08
02/21/17
14:08
Recommendations
Home Depot analyst commentary  »

Home Depot price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 15

    Mar

EXAS

Exact Sciences

$19.91

-0.26 (-1.29%)

14:08
02/21/17
02/21
14:08
02/21/17
14:08
Upgrade
Exact Sciences rating change  »

Exact Sciences upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

AG

First Majestic

$9.86

-0.2 (-1.99%)

14:06
02/21/17
02/21
14:06
02/21/17
14:06
Options
First Majestic call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

DVA

DaVita

$68.36

1.46 (2.18%)

, CI

Cigna

$145.74

2.18 (1.52%)

14:02
02/21/17
02/21
14:02
02/21/17
14:02
Hot Stocks
HealthCare Partners, Cigna form alliance to deliver new health plans in L.A. »

HealthCare Partners, a…

DVA

DaVita

$68.36

1.46 (2.18%)

CI

Cigna

$145.74

2.18 (1.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

AJG

Arthur J. Gallagher

$56.41

-0.53 (-0.93%)

14:00
02/21/17
02/21
14:00
02/21/17
14:00
Hot Stocks
Arthur J. Gallagher acquires Kelly Financial, terms not disclosed »

Arthur J. Gallagher &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXAS

Exact Sciences

$19.91

-0.26 (-1.29%)

13:55
02/21/17
02/21
13:55
02/21/17
13:55
Recommendations
Exact Sciences analyst commentary  »

Craig-Hallum would still…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

IMPV

Imperva

$45.70

0.8 (1.78%)

, CHKP

Check Point

$101.21

0.21 (0.21%)

13:51
02/21/17
02/21
13:51
02/21/17
13:51
Periodicals
Homeland Security having problems with computer systems, Reuters reports »

Some U.S. Department of…

IMPV

Imperva

$45.70

0.8 (1.78%)

CHKP

Check Point

$101.21

0.21 (0.21%)

SYMC

Symantec

$28.80

0.33 (1.16%)

PANW

Palo Alto Networks

$154.58

-0.18 (-0.12%)

QLYS

Qualys

$35.60

1.35 (3.94%)

FFIV

F5 Networks

$143.35

0.11 (0.08%)

FTNT

Fortinet

$37.46

0.215 (0.58%)

CUDA

Barracuda

$23.93

-0.07 (-0.29%)

FEYE

FireEye

$11.83

0.48 (4.23%)

PFPT

Proofpoint

$81.84

0.31 (0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 02

    Mar

  • 03

    Mar

  • 05

    Mar

K

Kellogg

$74.11

1.21 (1.66%)

13:51
02/21/17
02/21
13:51
02/21/17
13:51
Options
Hefty call spread in Kellogg as shares rally »

Hefty call spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

DBD

Diebold

$29.60

-0.5 (-1.66%)

13:47
02/21/17
02/21
13:47
02/21/17
13:47
Conference/Events
Diebold to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

MNK

Mallinckrodt

$53.66

-1.0799 (-1.97%)

13:46
02/21/17
02/21
13:46
02/21/17
13:46
Options
Mallinckrodt call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

HAS

Hasbro

$98.50

0.86 (0.88%)

13:45
02/21/17
02/21
13:45
02/21/17
13:45
Conference/Events
Hasbro management to meet with Wells Fargo »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

KFY

Korn/Ferry

$30.46

-0.1498 (-0.49%)

, GSK

GlaxoSmithKline

$41.50

0.16 (0.39%)

13:44
02/21/17
02/21
13:44
02/21/17
13:44
Hot Stocks
Korn Ferry Futurestep partners with GlaxoSmithKline over talent acquisition »

Futurestep division of…

KFY

Korn/Ferry

$30.46

-0.1498 (-0.49%)

GSK

GlaxoSmithKline

$41.50

0.16 (0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

13:35
02/21/17
02/21
13:35
02/21/17
13:35
General news
NY Fed accepted $163.3 B in daily reverse repos »

NY Fed accepted $163.3 B…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.